Park Ha Biological Technology Co., Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Xiaoqiu Zhang
- Full Time Employees
- 17
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 901 & 901-2 Wuxi People's Republic of China 214000
- IPO Date
- Jan 19, 2005
- CIK
- 0001986247
- Website
- parkha.cn
- Similar Companies
- Business
- Park Ha Biological Technology Co., Ltd. (PHH) is a Cayman Islands holding company primarily engaged in developing proprietary skincare products under the Park Ha brand; direct sales through company-operated stores; franchise alliances under Park Ha and Geni store names; and value-added light beauty experience services, a complimentary after-sales treatment demonstrating product efficacy in stores across China. Founded in 2016 and headquartered in Wuxi, Jiangsu Province, China, the company operates via subsidiaries including Jiangsu Park Ha Biological Technology Co., Ltd. for R&D and stores, Shanghai Park Ha Industrial Development Co., Ltd. for franchisee training, and Wuxi Xinzhan Enterprise Management Consulting Co., Ltd. for marketing and franchising; it serves primarily women seeking cost-effective skin solutions through nearly 128 products in 14 series covering basic physical protection, exfoliation, sebum film repair, microecological balance, and anti-aging categories, with star offerings such as the Little Blue Injection Serum for hydration, brightening and firming via multiple peptides, and freeze-dried powders featuring fibronectin and cherry blossom extract for firmer skin, produced via third-party manufacturers under strict quality controls and collaborations with institutions like Jiangnan University. As of April 30, 2024, it maintains two directly operated stores and 43 franchisees in China, predominantly under Park Ha; recent developments include a December 2024 Nasdaq initial public offering raising $4.8 million to fund directly-owned store expansion, proprietary product patent acquisitions, and ingredient supplier purchases for cost reduction, alongside 2025 announcements for an annual general meeting proposing share capital increases, dual-class share structure adoption, share consolidation, and auditor appointment, plus reported pharmaceutical R&D advancements and clinical trial progress driving stock gains.
PHH Mortgage Receives 2025 Fannie Mae Star Performer Award for Servicing Excellence
Park Ha Biological Technology Co., Ltd. Announces Pricing of US$2.45 Million Best-Efforts Follow-on Public Offering
Park Ha Biological Technology Co., Ltd. Announces Nasdaq Ticker Symbol Change to BYAH
PHH Mortgage Expands With Blend to Enhance Refinance and Home Equity Experiences for Borrowers
PHH Mortgage Receives Residential Servicing Ratings Upgrade from Fitch Ratings
PHH Mortgage Launches Proprietary Reverse Mortgage Product
PHH Mortgage Receives 2024 Fannie Mae Star Performer Award for Servicing Excellence
PHH Mortgage Enhances Proprietary Client Technology With AI Assistant
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
PHH Mortgage Partners with Blend to Revolutionize Home Lending Operations
Park Ha Biological Aims For U.S. IPO At Sky-High Valuation
U.S. IPO Weekly Recap: Small Issuers Close Out August IPO Market